Heilongjiang Tianlong Pharmaceutical, a wholly-owned subsidiary of China Sky One Medical, has recently completed R&D for eight different types of injections, obtaining production approval for three injections, including the propyl gallate injection.
Yan-Qing Liu, chairman, CEO and president of China Sky One Medical, said: “We are now in the last stage before formal production, and expect to launch the product in the middle of August.”